Ovid Therapeutics Appoints Ana C. Ward as Senior Vice President and General Counsel
September 06 2017 - 8:00AM
Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company
committed to developing medicines for patients with rare
neurological disorders, today announced the appointment of Ana C.
Ward as senior vice president and general counsel.
“With over 20 years of legal and bioscience
operational experience, along with a deep understanding of how to
achieve success within fast-growing life science companies, Ana
will be a strong addition to our leadership team,” said Jeremy
Levin, D.Phil., MB Chir, chairman of the board of directors and
chief executive officer of Ovid. “Her perspective, breadth of
experience, proven capability and expertise complements that of our
team. We are pleased to welcome Ana to the Ovid team.”
“With two rapidly progressing clinical programs,
this is an exciting time to join such a dynamic company,” said Ms.
Ward. “In just a few short years, Ovid has already established a
sound strategy to address an important area of need. I am excited
to contribute to the continued growth and success of the company
and work closely with its talented management team.”
Ms. Ward previously served as general counsel,
executive vice president of patient access and corporate
development, and board secretary of Rosetta Genomics, Ltd.,
overseeing public company reporting and executing licensing and
partnership activities. Prior to Rosetta Genomics, Ms. Ward held a
series of leadership roles within the Ambion family of companies,
including Ambion, Inc. (acquired by Applied Biosystems), Asuragen,
Inc. (a spin-off of Ambion, Inc.) and Mirna Therapeutics, Inc. (a
spin-off of Asuragen, Inc.), where she was responsible for managing
a diverse portfolio of legal matters such as intellectual property
claims, compliance, trademark clearance, and strategic business
interactions. Ms. Ward holds a bachelor of arts in French, a master
of science in molecular biology and a master of business
administration, all from the University of Texas, Austin, and a
juris doctorate from the University of Texas Law School. Ms. Ward
also holds a master of science in bioscience regulatory affairs
from Johns Hopkins University. She is admitted to practice law in
the State of Texas and is registered to practice before the United
States Patent & Trademark Office.
About Ovid TherapeuticsOvid
Therapeutics (NASDAQ: OVID) is a New York-based biopharmaceutical
company using its BoldMedicine™ approach to develop therapies that
transform the lives of patients with rare neurological disorders.
Ovid’s drug candidate, OV101, is currently in development for the
treatment of Angelman syndrome and Fragile X syndrome. Ovid has
initiated the Phase 2 STARS trial of OV101 in adults with Angelman
syndrome and a Phase 1 trial in adolescents with Angelman syndrome
or Fragile X syndrome. Ovid is also developing OV935 in
collaboration with Takeda Pharmaceutical Company Limited for the
treatment of rare epileptic encephalopathies and has initiated a
Phase 1b/2a trial of OV935.
For more information on Ovid, please visit
http://www.ovidrx.com/.
Contacts
Investors:
Burns McClellan
Steve Klass, 212-213-0006
Sklass@burnsmc.com
Media:
Pure Communications, Inc.
Katie Engleman, 910-509-3977
katie@purecommunicationsinc.com
Ovid Therapeutics (NASDAQ:OVID)
Historical Stock Chart
From Aug 2024 to Sep 2024
Ovid Therapeutics (NASDAQ:OVID)
Historical Stock Chart
From Sep 2023 to Sep 2024